Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.80 |
| ▸ | MAOA | P21397 | 3/20 | 0.80 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070405 | 1.00 | MAOB (0.80) | MAOBMAOASCN9A | |
| SCHEMBL8640659 | 0.96 | MAOB (0.74) | MAOBMAOASCN9A | |
| SCHEMBL8636182 | 0.94 | MAOB (0.78) | MAOBMAOASCN9A | |
| SCHEMBL8637846 | 0.91 | MAOB (0.72) | MAOBMAOASCN9A | |
| Hydrochloric Acid SCHEMBL8636518 | 0.90 | MAOB (0.71) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL194169 | 0.89 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL29358109 | 0.89 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL69350 | 0.89 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL31174565 | 0.89 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL69351 | 0.89 | MAOB (1.00) | MAOBMAOASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2070526-A1 | \"Methods for treatment of Parkinson's disease\ | Newron Pharmaceuticals S.p.A. (IT) | 2009-06-17 | — | — | EP | claimed |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-04-26 | — | — | US | claimed |
| EP-1613296-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | Newron Pharmaceuticals S.p.A. (IT) | 2006-01-11 | — | — | EP | claimed |
| WO-2004089353-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2004-10-21 | — | — | WO | claimed |
| US-9492410-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| US-20150150833-A1 | Methods For Treatment of Parkinson's Disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-8901176-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-12-02 | — | — | US | disclosed |
| US-20130053368-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-02-28 | — | — | US | disclosed |
| US-8283380-B2 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-10-09 | — | — | US | disclosed |
| EP-1613296-B1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARM SPA (IT) | 2009-07-01 | — | — | EP | disclosed |
| EP-2070526-A1 | \"Methods for treatment of Parkinson's disease\ | Newron Pharmaceuticals S.p.A. (IT) | 2009-06-17 | — | — | EP | disclosed |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-04-26 | — | — | US | disclosed |
| EP-1613296-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | Newron Pharmaceuticals S.p.A. (IT) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089353-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053368-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | MAOB, MAOA, SNCA | MAOB 1/4885MAOA 2/4885SCN9A 2416/4885 |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | MAOB, MAOA, SNCA | MAOB 1/4885MAOA 2/4885SCN9A 2416/4885 |
| US-20150150833-A1 | Methods For Treatment of Parkinson's Disease | MAOB, MAOA, SNCA | MAOB 1/4885MAOA 2/4885SCN9A 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.